South Africa
As announced to the Australian Stock Exchange on 8 August 2008, Virax received approval from the Medicines Control Council (MCC) in South Africa for further testing of its HIV Therapeutic Vaccine, VIR201.
This section will be updated in respect of participating clinical sites and trial information as the information comes to hand.